Alder's Antibody Selection (ABS) Process
Alder has developed a unique antibody identification process that is able to identify very potent and rare therapeutic antibodies. The process enables rapid discovery directly from an immunized host using proprietary biological techniques. Unlike existing technologies, Alder’s ABS process has the ability to assess function directly at the outset while allowing broad epitope coverage.
- Proven operational in a variety of hosts
- Fully exploits the immune system repertoire
- Supports extensive epitope coverage and diversity
- Pairs functional activity with antibody identification
Alder's ABS process allows for the unique generation of multiple high-quality, function-modifying antibodies. This improves speed and efficiency in the discovery process.
Paired with Alder’s MabXpress yeast expression technology, Alder’s ABS process accelerates the progression of antibodies into in vivo studies and human clinical trials. In fact, we were able to bring each of our two product candidates, ALD403 and Clazakizumab, from discovery initiation against the disease target to dosing of patients in clinical trials in 20 months.
ABS Timeline for Human Therapeutic Generation